Tetramethylcurcumine

Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects[1][2].

52328-97-9

FLLL31

12352005

H413

Apoptosis; STAT

Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt

COVID-19-immunoregulation

Cancer; Inflammation/Immunology

99.91

DMSO : 100 mg/mL (ultrasonic)

COC1=C(C=CC(/C=C/C(C(C)(C)C(/C=C/C2=CC(OC)=C(OC)C=C2)=O)=O)=C1)OC

C25H28O6

424.49

H413

[1]Lin L, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010 Mar 15;70 (6) :2445-54.|[2]Yuan S, et al. FLLL31, a derivative of curcumin, attenuates airway inflammation in a multi-allergen challenged mouse model. Int Immunopharmacol. 2014 Jul;21 (1) :128-36.

Room Temperature

4°C (Powder, sealed storage, away from moisture and light)

http://file.medchemexpress.com/batch_PDF/HY-N2521/Tetramethylcurcumin-SDS-MedChemExpress.pdf

Natural Products

No Development Reported

STAT3